739 related articles for article (PubMed ID: 15507547)
1. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
Liang K; Kim CH; Vaziri ND
Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
[TBL] [Abstract][Full Text] [Related]
2. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.
Vaziri ND; Liang K
Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
Liang K; Vaziri ND
Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
[TBL] [Abstract][Full Text] [Related]
4. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Vaziri ND; Liang K
Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.
Vaziri ND; Sato T; Liang K
Kidney Int; 2003 May; 63(5):1756-63. PubMed ID: 12675851
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.
Roberts CK; Liang K; Barnard RJ; Kim CH; Vaziri ND
Kidney Int; 2004 Oct; 66(4):1503-11. PubMed ID: 15458444
[TBL] [Abstract][Full Text] [Related]
7. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
Vaziri ND; Liang KH
Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.
Vaziri ND; Liang K; Parks JS
Kidney Int; 2001 Jun; 59(6):2192-6. PubMed ID: 11380821
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions.
Vaziri ND; Liang K; Azad H
J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Liang K; Vaziri ND
Nephrol Dial Transplant; 1997 Jul; 12(7):1381-6. PubMed ID: 9249773
[TBL] [Abstract][Full Text] [Related]
11. Effects of gender on hepatic HMG-CoA reductase, cholesterol 7alpha-hydroxylase, and LDL receptor in hereditary analbuminemia.
Shin Y; Vaziri ND; Willekes N; Kim CH; Joles JA
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E993-8. PubMed ID: 16030068
[TBL] [Abstract][Full Text] [Related]
12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes in cholesterol metabolism in macrosomic offspring of rats with streptozotocin-induced diabetes.
Merzouk H; Madani S; Boualga A; Prost J; Bouchenak M; Belleville J
J Lipid Res; 2001 Jul; 42(7):1152-9. PubMed ID: 11441144
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
Liang K; Vaziri ND
Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E676-81. PubMed ID: 12217884
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ovarian cholesterol metabolism: control of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase.
Schuler LA; Toaff ME; Strauss JF
Endocrinology; 1981 Apr; 108(4):1476-86. PubMed ID: 7472277
[TBL] [Abstract][Full Text] [Related]
16. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
17. Impact of an enriched-cholesterol diet on enzymatic cholesterol metabolism during rabbit gestation.
Montoudis A; Boileau S; Simoneau L; Lafond J
Life Sci; 2003 Aug; 73(11):1463-77. PubMed ID: 12850506
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol metabolism: regulatory effects of the vagus in the normal and diabetic animal.
Scott LM; Tomkin GH
Diabetes Res; 1985 Nov; 2(6):313-7. PubMed ID: 4075700
[TBL] [Abstract][Full Text] [Related]
19. Compensatory responses to inhibition of hepatic squalene synthase.
Lopez D; Chambers CM; Keller RK; Ness GC
Arch Biochem Biophys; 1998 Mar; 351(2):159-66. PubMed ID: 9514656
[TBL] [Abstract][Full Text] [Related]
20. Effects of dietary soybean lecithin on plasma lipid transport and hepatic cholesterol metabolism in rats.
LeBlanc MJ; Brunet S; Bouchard G; Lamireau T; Yousef IM; Gavino V; Lévy E; Tuchweber B
J Nutr Biochem; 2003 Jan; 14(1):40-8. PubMed ID: 12559476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
